VB Weekly Highlights: Telemedicine Takes Center Stage with Major IPO Filing
Sep 28, 2015 08:07
CST Updated
08:07
→_→ Events and Perspectives
Last week, the most high-profile event across China and even globally was the U.S. visit by the beloved patriotic couple, “President Xi and Madame Peng.”
(VCBeat has provided a detailed analysis; please click here)Hololens）, and Ms. Peng Liyuan visited the Fred Hutchinson Cancer Research Center in Seattle, accompanied by Bill and Melinda Gates.
What does this indicate? It indicatesPrioritize Health While Combining Work and Travel。
Of course, the greatest attention remains focused on Guahao.com-WeDoctor Group, which announced a $394 million financing round. How will such a substantial sum be allocated?
First, invest $300 million to build a national tiered diagnosis and treatment platform based on the internet; second, invest $150 million (with $94 million from this round of financing and an additional $56 million from the company’s reserve funds) to jointly establish five regional surgical centers with leading medical institutions across China, providing users with closed-loop online and offline medical and health services.(For details, click “Exclusive: After Securing $394 Million in Funding, How Is Guahao.com Building the Internet’s “Kaiser Permanente”?”）
Therefore,
In addition, according to VCBeat's data statistics, by comparisonThe Hottest Field Last Week Was Telemedicine.
Yes,Kang'enbei Invests RMB 26 Million in Shanghai Xinfangxun.
Last week, Conba announced that, in line with its strategic layout of the internet healthcare industry chain, it plans to inject RMB 26 million into Shanghai Xinfangxun Communication Technology Co., Ltd. Of this amount, RMB 3 million will be allocated to registered capital, accounting for 20% of Shanghai Xinfangxun’s registered capital after the capital increase, while the remaining RMB 23 million will be credited to the capital reserve.
According to VCBeat, Shanghai Xinfangxun is a provider of internet-based telemedicine platform solutions and an R&D enterprise specializing in remote medical monitoring terminals. The company focuses on the integration of mobile internet with healthcare and health management, holding multiple patented technologies in this field. Additionally, it has expanded its business operations to cities including Beijing, Xiamen, and Hangzhou.
Conba stated that this investment has industrial synergy conditions with the company's prescription drug marketing, which will provide opportunities for the company to lay out the Internet medical industry chain and achieve industrial upgrading.
Additionally,Zoll Acquires Israeli Wearable Cardiac Monitor Manufacturer for $35 Million.
Recently, U.S.-based Zoll Medical acquired Israeli wearable cardiac device manufacturer Kyma Medical Technologies for $35 million. Kyma Medical Technologies designs wearable remote monitoring devices for patients with congestive heart failure.
According to VCBeat, Zoll’s acquisition of Kyma Medical aims to broaden its product portfolio, incorporate new technologies, and improve therapeutic outcomes for heart failure patients with fluid accumulation issues. Furthermore, leveraging Zoll’s existing network will enable Kyma’s technology to better penetrate the global market.
In addition, other covered areas include cross-border healthcare, medical check-ups, and health insurance.
For example, internet healthcare companies rooted in enterprises include Chunyu International and Quyi Network.
Last week,Spring Rain InternationalThe “Healthcare Without Borders” and Chunyu Cross-Border Healthcare Service Platform Product Launch Press Conference was held in Beijing, whereLaunched multiple streamlined, customized cross-border medical service products.
The examination items include a routine full-body physical examination and screening for digestive system diseases.For example, South Korea’s gastrointestinal screening health checkup packages, Japan’s early cancer detection screening programs, Singapore’s premium specialized cardiac examination packages, and Hong Kong’s “Jian Ai Yi Sheng” individual health checkup products.
Xiong Juan, CEO of Chunyu International, stated that cross-border medical checkups are currently a form of high-end consumption. Chunyu International eliminates ancillary service costs and excessive intermediary markups, focusing solely on delivering the core medical services that matter most to users.
Furthermore, Xiong Juan stated that the platform will continue to integrate comprehensive medical and health resources in the future, onboarding more cross-border medical institutions that meet established standards. The platform maintains a “zero-tolerance” policy toward service deficiencies and is committed to providing full compensation for major diseases missed during medical examinations.
Quyi.com Partners with 1Drug.com to Bridge the Last Mile of Online Hospital Services.
Last week,Quyi Network Announces Strategic Partnership with 111.com to Jointly Build an Internet Healthcare O2O Closed LoopIn the future, 111.com will fully integrate into the “Quyi Network Hospital” service ecosystem as a strategic partner, enabling users to experience end-to-end online healthcare services—from consultation to prescription and medication delivery—without leaving their homes.
This collaboration with 111.com also represents a concrete manifestation of the business model implementation under Quyi Network’s “Hospital+” strategy.
As a key strategic initiative released by Quyi.com this year, the “Hospital+” strategy leverages the platform layer as its entry point and adopts a business model in which the application layer integrates third-party services—such as pharmacies, insurance institutions, and pharmaceutical e-commerce platforms—to build a three-tiered internet healthcare ecosystem. Relying on the open “Hospital+” platform, Quyi.com’s “Quyi Online Hospital” service will achieve interoperability with the platform services of 111.com (Yi Yao Wang), a leading pharmaceutical e-commerce company. In the future, Quyi.com will provide users with the “Quyi Online Hospital” service platform at the front end; physical hospitals will utilize this platform to deliver online consultation services and generate electronic prescription orders; and 111.com will fulfill these orders through online dispensing and offline delivery, thereby creating a closed-loop O2O (online-to-offline) service model that integrates online and offline operations.
Kangzhijia and JD Daojia Reach Strategic Partnership.
This strategic partnership,Both parties will use “pharmaceuticals” as the entry point, covering a wide range of categories for household essential and urgently needed medications, to comprehensively meet users’ medication purchasing needs.Furthermore, both parties will engage in in-depth cooperation across five major health categories, including medical devices, pharmaceutical packaging materials, healthcare products, instruments and equipment, and adult products.
For example, traditional entities include medical institutions and pharmaceutical companies.
Xiaotangshan Hospital to Establish Beijing-Tianjin-Hebei Rehabilitation Information Platform.
Recently, Ping Zhao, President of Xiaotangshan Hospital, stated that,To meet the rehabilitation needs of more patients, Xiaotangshan Hospital has established referral criteria and procedures for transferred patients and built a rehabilitation information-sharing platform for the Beijing-Tianjin-Hebei region.
Xiaotangshan Hospital stated that the referring hospital would dispatch experts to provide technical guidance and support when necessary, and offer referred patients conveniences such as priority consultations, priority examinations, and priority hospitalization. Furthermore, if a patient’s condition deteriorates, they can be transferred back to the original referring hospital for further treatment.
In addition, Xiaotangshan Hospital is establishing a rehabilitation network in collaboration with multiple hospitals, with plans to create a shared platform for rehabilitation information data, enabling patient information to be shared on the platform.
Bayer Ramps Up Its Life Sciences Business.
Recently,Bayer announced that, effective January 1, 2016, its business operations would be organized into three divisions: Pharmaceuticals, Consumer Health, and Crop Science.
It is reported that within the new organizational structure, Bayer HealthCare will be split, with its Radiology business integrated into the Pharmaceuticals Division and its Consumer Health business merged into the Consumer Care Division. Bayer CropScience will be transformed into the Crop Science Division. Going forward, Bayer will consolidate its portfolio of prescription drugs in both the generics and specialty segments, along with the Radiology business, under the unified Pharmaceuticals Division.
Marijn Dekkers, Chairman of the Board of Management of Bayer AG, stated that the new organization aims to support Bayer’s strategy as a leading life sciences company to the greatest extent possible, and to enhance competitiveness by boosting innovation, strengthening customer orientation, and optimizing business processes.
Baiyunshan and Siemens Join Hands to Co-Create the Future of Medical Diagnostics.
Last week, Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. announced that it intends to sign the “Letter of Intent for Cooperation on the China Medical Diagnostic Center Project” with Siemens Shanghai.
The two parties intend to jointly establish a company to operate diagnostic centers covering imaging diagnosis, health check-ups, and in vitro diagnostics, as well as other businesses agreed upon by both parties. Among them, the Company or its wholly-owned subsidiary, Guangzhou Baiyunshan Medical Health Industry Investment Co., Ltd., will hold 51% of the equity interest in the joint venture, while Siemens Shanghai will hold 49%.
This collaboration will help GPC Baiyunshan expand its medical services business and holds significant strategic importance for the company’s future development as it enters the medical diagnostics sector.
Furthermore, innovators in the biotechnology sector and giants in the health checkup industry have not halted their strides toward development.
Recently,The “Health Checkup and Precision Medical Services Alliance,” initiated by Meinian Onehealth, one of the giants in China’s health checkup industry, and comprising ten corporate members including Ciming Health Checkup, AstraZeneca, Taikang Life Insurance, and Rich Healthcare Group, was established in Zhengzhou.
Yu Rong, Chairman of Meinian Onehealth Healthcare, stated, “Leveraging the platform traffic generated by health checkups, this alliance extends upstream and downstream to build an open, collaborative, and mutually beneficial platform that raises industry standards.” According to available information, the alliance’s members span professional health screening, health management associations, medical diagnostics, biopharmaceuticals, and health insurance, forming a comprehensive ecosystem that covers early-stage testing and prevention through to later-stage diagnosis, treatment, and health management.
It can thus be seen that Meinian Onehealth’s platform strategy has begun to take shape following its alliance with Ciming Health Checkup and the completion of its back-door listing.
Vcanbio, a stem cell company, has also entered the health insurance market.
Zhongyuan Union Cell & Gene Engineering Corp. announced last week that it had signed a Strategic Cooperation Agreement with PICC Health Insurance Company Limited, under which both parties will engage in in-depth collaboration in areas including health management, anti-aging, healthcare, investment in the elderly care industry, and financial investments.
Under the terms of the agreement, both parties will explore the establishment of an integrated health protection plan that combines health insurance, health management, elderly care and nursing, and life science technologies. In the areas of health insurance and health management services, Vcanbio will provide PICC Health with relevant life science products and services required for the integrated health protection plan on preferential terms.
In the field of medical data services, both parties will share healthcare data resources.
In addition, both parties will actively explore various forms of capital cooperation to broaden the scope and diversify the modes of collaboration. For instance, in sales activities, they will jointly work on customer development and provide each other with necessary facilitation. As stipulated in the agreement, both parties will actively evaluate agency sales arrangements or the referral of each other’s products and services to their respective customers, and will offer relevant products and services to each other or to each other’s customers on preferential terms.
Of course, do not forget the BAT companies that have been “eyeing covetously.”
Recently,Alibaba Cloud Partners with Hangzhou Lianzhong to Launch Medical Imaging Cloud Storage Service, helping healthcare institutions store imaging data such as CT and MRI scans on an infinitely scalable cloud platform. By leveraging multi-line BGP connectivity and top-tier CDN nodes across China, it ensures smooth access and meets the growing storage demands for large volumes of images, medical scans, and videos. Hospitals can thereby reduce costs by approximately 50%.
It is reported that the Affiliated Hospital of Inner Mongolia Medical University has taken the lead in migrating all its medical data to the cloud and is poised to establish a “Telemedicine Consultation Network” with 115 secondary hospitals at the banner, county, and district levels across 12 leagues and cities within the region. This initiative will enable two-way patient referrals, remote consultations, and regional collaboration in medical imaging among hospitals at various levels, serving as a model for the entire autonomous region.
There are also tech giants that “love to engage in verbal sparring.” Samsung, for example.
Last week,Samsung S Health app is available to all Android devices.
In July 2012, Samsung launched the S Health app service, which was exclusively available to users of Samsung devices.
But from now on, all Android users can download and use the S Health app. It can track daily activities and help users create training plans to achieve their fitness goals.
Additionally, the app provides a functional dashboard that allows users to quickly browse all statistics and information. This dashboard can be customized at will, enabling users to add or remove goals, programs, screen tracking, and more.
Not only that, the app can also manage and utilize the built-in sensors of smartphones to measure heart rate, blood oxygen saturation, UV exposure, and more.
→_→ VCBeat Exclusive
→_→ Healthcare Reform
★Three Departments in Zhejiang Jointly Issue Document: Allowing a 30% Price Increase for Certain Drugs.
On September 23, the Zhejiang Provincial Department of Human Resources and Social Security, the Health and Family Planning Commission, and the Price Bureau jointly issued a document to solicit opinions on the “Notice on Ensuring Policy Coordination for Basic Medical Insurance Drugs Following Drug Price Reforms.”
The notice states that manufacturers of drugs included in the national and provincial lists of low-priced medicines may independently adjust the prices of these drugs within prescribed limits, based on the provincial winning bid prices, provided that the daily cost does not exceed RMB 3 for western medicines and RMB 5 for traditional Chinese medicines.
In this instance, Zhejiang Province has taken the initiative to allow enterprises to raise prices of low-cost drugs within a certain range under national standards, which can be regarded as an important practical measure in liberalizing drug pricing.
The notice also pointed out that, following the implementation of the rules for medical insurance payment standards, the prices of low-cost drugs shall be administered in accordance with the policies governing such standards.
Furthermore, the Notice states that for non-winning bid drugs within the scope of basic medical insurance coverage (excluding emergency drugs), if long-term record-based procurement is required, medical institutions shall submit applications to the Provincial Health and Family Planning Commission in accordance with the provisions of the "Zhejiang Province Online Centralized Drug Procurement Record-Based Procurement Management Measures (Trial)." Upon review by the Provincial Health and Family Planning Commission and the Provincial Department of Human Resources and Social Security, the measures shall be implemented after being announced by the Office of the Leading Group for Provincial Centralized Drug Procurement.
→_→ Data
◆Next 5 Years: Global Pharmaceutical Market to Reach Trillions, Anti-Cancer Drugs Near $150 Billion, and Tumor Immunotherapy Hits $40 Billion
Over the next five years, the global pharmaceutical market is projected to grow at a compound annual growth rate (CAGR) of 4%–7%, reaching $1.27 trillion by 2018. Within this market, generics are expected to expand at a rate of 7%–10%, attaining a value of $606 billion by 2018 and accounting for 48% of the total pharmaceutical market size.
Last year, the anticancer drug market generated $100 billion in revenue. By 2018, the market is projected to reach $147 billion, with a compound annual growth rate (CAGR) of 11.6%, indicating that the research and development of anticancer drugs can yield substantial profits.
According to forecasts by Goldman Sachs, the market for cancer immunotherapy was expected to reach $31 billion by 2020, while consulting firm Leerink Partners projected that the market would grow to $40 billion over the following decade.
Currently, the global anti-cancer drug market is largely dominated by Roche, Novartis, Merck & Co., and Bristol-Myers Squibb. However, Pfizer, known for producing Viagra (for erectile dysfunction) and Lipitor (a cholesterol-lowering medication), has recently expressed its intention to enter this market.
◆GlobalData: The Global HIV/AIDS Therapy Market Will Reach $15.3 Billion in 2023.
According to a report by the research and consulting firm GlobalData,The market value of human immunodeficiency virus (HIV) therapies will increase from $14 billion in 2013 to $15.3 billion in 2023, with a compound annual growth rate (CAGR) of 0.9% across the nine major markets (the United States, France, Germany, Italy, Spain, the United Kingdom, Japan, Brazil, and China)., representing a lower compound annual growth rate.
Moreover, although the overall market size for HIV/AIDS will remain relatively stable in the coming years, the HIV/AIDS therapeutics market is expected to shift toward integrase inhibitors and single-tablet regimens. This trend is particularly pronounced in the United States, as fiscal austerity measures continue to be the primary obstacle to market growth in other countries.
However, GlobalData’s report indicates that integrase inhibitors for HIV treatment, such as ViiV Healthcare’s Triumeq and Gilead’s Quad 2, will offset the impact of generic drugs on the market in the coming years.
◆Global Biopharmaceutical Market: Set to Expand to $600 Billion Over the Next Seven Years.
According to Grand View Research, the global biotechnology market size was $270.5 billion in 2013, driven by growing demand for recombinant technology, pharmaceutical biotechnology, and DNA sequencing technologies in disease diagnosis and treatment.The global biotechnology market is projected to grow at a compound annual growth rate (CAGR) of 12.3%, reaching $606.8 billion by 2020.
→_→ New Technology
◆China’s First Intelligent Digital Hearing Aid Chip Successfully Developed.
Recently, China’s first intelligent digital hearing aid chip was successfully developed by the Institute of Microelectronics of the Chinese Academy of Sciences. As the country’s first core System-on-Chip (SoC) for hearing aids, it represents a true single-chip, fully integrated hearing aid solution. The chip has passed industry-standard testing for hearing aids, with its performance and power consumption metrics meeting the requirements for international mid-range hearing aid products.
The hearing aid SoC chip adopts a single-chip fully integrated solution, in which the low-noise AFE includes an adaptive pre-amplification circuit (PGA) and a low-noise 16-bit ADC; the low-power DSP comprises an Application-Specific Instruction-set Processor (ASIP) and several coprocessors. Based on this SoC chip, a typical hearing aid system can be built by simply equipping it with a microphone, speaker, EEPROM, zinc-air battery, and a few capacitors. This SoC chip can also be programmed for applications in other fields such as sound acquisition and speech noise reduction.
◆Massachusetts General Hospital Develops New Smartphone-Connected Device for Rapid Cancer Diagnosis.
Two researchers at Massachusetts General Hospital have developed a device, D3, that can deliver cancer diagnostic results within one hour using only a smartphone, eliminating the need for invasive biopsies.
The D3 or Digital Splitting Diagnostic System is a compact device that connects to a smartphone camera, transforming it into a powerful microscope for analyzing samples from blood, fine-needle aspiration biopsies, Pap smears, or sparse cell populations. The system utilizes specialized antibodies that cause cancer cells to fluoresce upon detection.
The device has undergone cohort testing to compare its performance against diagnostic results from expert clinicians. One of the test objectives was to classify cervical biopsy samples as high-risk, low-risk, or benign; another objective was to differentiate among four types of benign and malignant tumors.
→_→ Capital
Last week, the most high-profile event across China and even globally was the U.S. visit by the beloved patriotic couple, “President Xi and Madame Peng.”
(VCBeat has provided a detailed analysis; please click here)Hololens）, and Ms. Peng Liyuan visited the Fred Hutchinson Cancer Research Center in Seattle, accompanied by Bill and Melinda Gates.
What does this indicate? It indicatesPrioritize Health While Combining Work and Travel。
Of course, the greatest attention remains focused on Guahao.com-WeDoctor Group, which announced a $394 million financing round. How will such a substantial sum be allocated?
First, invest $300 million to build a national tiered diagnosis and treatment platform based on the internet; second, invest $150 million (with $94 million from this round of financing and an additional $56 million from the company’s reserve funds) to jointly establish five regional surgical centers with leading medical institutions across China, providing users with closed-loop online and offline medical and health services.(For details, click “Exclusive: After Securing $394 Million in Funding, How Is Guahao.com Building the Internet’s “Kaiser Permanente”?”）
Therefore,
In addition, according to VCBeat's data statistics, by comparisonThe Hottest Field Last Week Was Telemedicine.
Yes,Kang'enbei Invests RMB 26 Million in Shanghai Xinfangxun.
Last week, Conba announced that, in line with its strategic layout of the internet healthcare industry chain, it plans to inject RMB 26 million into Shanghai Xinfangxun Communication Technology Co., Ltd. Of this amount, RMB 3 million will be allocated to registered capital, accounting for 20% of Shanghai Xinfangxun’s registered capital after the capital increase, while the remaining RMB 23 million will be credited to the capital reserve.
According to VCBeat, Shanghai Xinfangxun is a provider of internet-based telemedicine platform solutions and an R&D enterprise specializing in remote medical monitoring terminals. The company focuses on the integration of mobile internet with healthcare and health management, holding multiple patented technologies in this field. Additionally, it has expanded its business operations to cities including Beijing, Xiamen, and Hangzhou.
Conba stated that this investment has industrial synergy conditions with the company's prescription drug marketing, which will provide opportunities for the company to lay out the Internet medical industry chain and achieve industrial upgrading.
Additionally,Zoll Acquires Israeli Wearable Cardiac Monitor Manufacturer for $35 Million.
Recently, U.S.-based Zoll Medical acquired Israeli wearable cardiac device manufacturer Kyma Medical Technologies for $35 million. Kyma Medical Technologies designs wearable remote monitoring devices for patients with congestive heart failure.
According to VCBeat, Zoll’s acquisition of Kyma Medical aims to broaden its product portfolio, incorporate new technologies, and improve therapeutic outcomes for heart failure patients with fluid accumulation issues. Furthermore, leveraging Zoll’s existing network will enable Kyma’s technology to better penetrate the global market.
In addition, other covered areas include cross-border healthcare, medical check-ups, and health insurance.
For example, internet healthcare companies rooted in enterprises include Chunyu International and Quyi Network.
Last week,Spring Rain InternationalThe “Healthcare Without Borders” and Chunyu Cross-Border Healthcare Service Platform Product Launch Press Conference was held in Beijing, whereLaunched multiple streamlined, customized cross-border medical service products.
The examination items include a routine full-body physical examination and screening for digestive system diseases.For example, South Korea’s gastrointestinal screening health checkup packages, Japan’s early cancer detection screening programs, Singapore’s premium specialized cardiac examination packages, and Hong Kong’s “Jian Ai Yi Sheng” individual health checkup products.
Xiong Juan, CEO of Chunyu International, stated that cross-border medical checkups are currently a form of high-end consumption. Chunyu International eliminates ancillary service costs and excessive intermediary markups, focusing solely on delivering the core medical services that matter most to users.
Furthermore, Xiong Juan stated that the platform will continue to integrate comprehensive medical and health resources in the future, onboarding more cross-border medical institutions that meet established standards. The platform maintains a “zero-tolerance” policy toward service deficiencies and is committed to providing full compensation for major diseases missed during medical examinations.
Quyi.com Partners with 1Drug.com to Bridge the Last Mile of Online Hospital Services.
Last week,Quyi Network Announces Strategic Partnership with 111.com to Jointly Build an Internet Healthcare O2O Closed LoopIn the future, 111.com will fully integrate into the “Quyi Network Hospital” service ecosystem as a strategic partner, enabling users to experience end-to-end online healthcare services—from consultation to prescription and medication delivery—without leaving their homes.
This collaboration with 111.com also represents a concrete manifestation of the business model implementation under Quyi Network’s “Hospital+” strategy.
As a key strategic initiative released by Quyi.com this year, the “Hospital+” strategy leverages the platform layer as its entry point and adopts a business model in which the application layer integrates third-party services—such as pharmacies, insurance institutions, and pharmaceutical e-commerce platforms—to build a three-tiered internet healthcare ecosystem. Relying on the open “Hospital+” platform, Quyi.com’s “Quyi Online Hospital” service will achieve interoperability with the platform services of 111.com (Yi Yao Wang), a leading pharmaceutical e-commerce company. In the future, Quyi.com will provide users with the “Quyi Online Hospital” service platform at the front end; physical hospitals will utilize this platform to deliver online consultation services and generate electronic prescription orders; and 111.com will fulfill these orders through online dispensing and offline delivery, thereby creating a closed-loop O2O (online-to-offline) service model that integrates online and offline operations.
Kangzhijia and JD Daojia Reach Strategic Partnership.
This strategic partnership,Both parties will use “pharmaceuticals” as the entry point, covering a wide range of categories for household essential and urgently needed medications, to comprehensively meet users’ medication purchasing needs.Furthermore, both parties will engage in in-depth cooperation across five major health categories, including medical devices, pharmaceutical packaging materials, healthcare products, instruments and equipment, and adult products.
For example, traditional entities include medical institutions and pharmaceutical companies.
Xiaotangshan Hospital to Establish Beijing-Tianjin-Hebei Rehabilitation Information Platform.
Recently, Ping Zhao, President of Xiaotangshan Hospital, stated that,To meet the rehabilitation needs of more patients, Xiaotangshan Hospital has established referral criteria and procedures for transferred patients and built a rehabilitation information-sharing platform for the Beijing-Tianjin-Hebei region.
Xiaotangshan Hospital stated that the referring hospital would dispatch experts to provide technical guidance and support when necessary, and offer referred patients conveniences such as priority consultations, priority examinations, and priority hospitalization. Furthermore, if a patient’s condition deteriorates, they can be transferred back to the original referring hospital for further treatment.
In addition, Xiaotangshan Hospital is establishing a rehabilitation network in collaboration with multiple hospitals, with plans to create a shared platform for rehabilitation information data, enabling patient information to be shared on the platform.
Bayer Ramps Up Its Life Sciences Business.
Recently,Bayer announced that, effective January 1, 2016, its business operations would be organized into three divisions: Pharmaceuticals, Consumer Health, and Crop Science.
It is reported that within the new organizational structure, Bayer HealthCare will be split, with its Radiology business integrated into the Pharmaceuticals Division and its Consumer Health business merged into the Consumer Care Division. Bayer CropScience will be transformed into the Crop Science Division. Going forward, Bayer will consolidate its portfolio of prescription drugs in both the generics and specialty segments, along with the Radiology business, under the unified Pharmaceuticals Division.
Marijn Dekkers, Chairman of the Board of Management of Bayer AG, stated that the new organization aims to support Bayer’s strategy as a leading life sciences company to the greatest extent possible, and to enhance competitiveness by boosting innovation, strengthening customer orientation, and optimizing business processes.
Baiyunshan and Siemens Join Hands to Co-Create the Future of Medical Diagnostics.
Last week, Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. announced that it intends to sign the “Letter of Intent for Cooperation on the China Medical Diagnostic Center Project” with Siemens Shanghai.
The two parties intend to jointly establish a company to operate diagnostic centers covering imaging diagnosis, health check-ups, and in vitro diagnostics, as well as other businesses agreed upon by both parties. Among them, the Company or its wholly-owned subsidiary, Guangzhou Baiyunshan Medical Health Industry Investment Co., Ltd., will hold 51% of the equity interest in the joint venture, while Siemens Shanghai will hold 49%.
This collaboration will help GPC Baiyunshan expand its medical services business and holds significant strategic importance for the company’s future development as it enters the medical diagnostics sector.
Furthermore, innovators in the biotechnology sector and giants in the health checkup industry have not halted their strides toward development.
Recently,The “Health Checkup and Precision Medical Services Alliance,” initiated by Meinian Onehealth, one of the giants in China’s health checkup industry, and comprising ten corporate members including Ciming Health Checkup, AstraZeneca, Taikang Life Insurance, and Rich Healthcare Group, was established in Zhengzhou.
Yu Rong, Chairman of Meinian Onehealth Healthcare, stated, “Leveraging the platform traffic generated by health checkups, this alliance extends upstream and downstream to build an open, collaborative, and mutually beneficial platform that raises industry standards.” According to available information, the alliance’s members span professional health screening, health management associations, medical diagnostics, biopharmaceuticals, and health insurance, forming a comprehensive ecosystem that covers early-stage testing and prevention through to later-stage diagnosis, treatment, and health management.
It can thus be seen that Meinian Onehealth’s platform strategy has begun to take shape following its alliance with Ciming Health Checkup and the completion of its back-door listing.
Vcanbio, a stem cell company, has also entered the health insurance market.
Zhongyuan Union Cell & Gene Engineering Corp. announced last week that it had signed a Strategic Cooperation Agreement with PICC Health Insurance Company Limited, under which both parties will engage in in-depth collaboration in areas including health management, anti-aging, healthcare, investment in the elderly care industry, and financial investments.
Under the terms of the agreement, both parties will explore the establishment of an integrated health protection plan that combines health insurance, health management, elderly care and nursing, and life science technologies. In the areas of health insurance and health management services, Vcanbio will provide PICC Health with relevant life science products and services required for the integrated health protection plan on preferential terms.
In the field of medical data services, both parties will share healthcare data resources.
In addition, both parties will actively explore various forms of capital cooperation to broaden the scope and diversify the modes of collaboration. For instance, in sales activities, they will jointly work on customer development and provide each other with necessary facilitation. As stipulated in the agreement, both parties will actively evaluate agency sales arrangements or the referral of each other’s products and services to their respective customers, and will offer relevant products and services to each other or to each other’s customers on preferential terms.
Of course, do not forget the BAT companies that have been “eyeing covetously.”
Recently,Alibaba Cloud Partners with Hangzhou Lianzhong to Launch Medical Imaging Cloud Storage Service, helping healthcare institutions store imaging data such as CT and MRI scans on an infinitely scalable cloud platform. By leveraging multi-line BGP connectivity and top-tier CDN nodes across China, it ensures smooth access and meets the growing storage demands for large volumes of images, medical scans, and videos. Hospitals can thereby reduce costs by approximately 50%.
It is reported that the Affiliated Hospital of Inner Mongolia Medical University has taken the lead in migrating all its medical data to the cloud and is poised to establish a “Telemedicine Consultation Network” with 115 secondary hospitals at the banner, county, and district levels across 12 leagues and cities within the region. This initiative will enable two-way patient referrals, remote consultations, and regional collaboration in medical imaging among hospitals at various levels, serving as a model for the entire autonomous region.
There are also tech giants that “love to engage in verbal sparring.” Samsung, for example.
Last week,Samsung S Health app is available to all Android devices.
In July 2012, Samsung launched the S Health app service, which was exclusively available to users of Samsung devices.
But from now on, all Android users can download and use the S Health app. It can track daily activities and help users create training plans to achieve their fitness goals.
Additionally, the app provides a functional dashboard that allows users to quickly browse all statistics and information. This dashboard can be customized at will, enabling users to add or remove goals, programs, screen tracking, and more.
Not only that, the app can also manage and utilize the built-in sensors of smartphones to measure heart rate, blood oxygen saturation, UV exposure, and more.
→_→ VCBeat Exclusive
- Gu Beini's Column
- What Will Future Commercial Health Insurance Look Like?
- What Policies Have Been Issued by Provinces Across China to Promote Tiered Diagnosis and Treatment?
- Exclusive: After Securing $394 Million in Funding, How Is Guahao.com Building the “Kaiser Permanente” of the Internet?
- Xinyi International: Bridging “Internet + Healthcare” with Telemedicine
- Andon Health: Becoming the “Apple” of the Mobile Healthcare Industry
- Chunyu International: Becoming the “Ctrip” of Cross-Border Healthcare
- [Cardiovascular Series] Alibaba Cloud’s “Peace of Mind on the Cloud” Alliance: Aggregating Big Data on Human Health to Explore Precision Medicine
- Xingxiangyuan: Here, Every Doctor Is an Entrepreneur
- Japanese Rehabilitation Expert Tetsuya Asakawa: My Dream Is to Establish a Comprehensive Rehabilitation System in China
- Internet Healthcare Will See a Breakout Year: 2020
- How Can Big Data Empower the ICU?
- If you don’t even understand these few terms, what business do you have in the internet healthcare circle?
→_→ Healthcare Reform
★Three Departments in Zhejiang Jointly Issue Document: Allowing a 30% Price Increase for Certain Drugs.
On September 23, the Zhejiang Provincial Department of Human Resources and Social Security, the Health and Family Planning Commission, and the Price Bureau jointly issued a document to solicit opinions on the “Notice on Ensuring Policy Coordination for Basic Medical Insurance Drugs Following Drug Price Reforms.”
The notice states that manufacturers of drugs included in the national and provincial lists of low-priced medicines may independently adjust the prices of these drugs within prescribed limits, based on the provincial winning bid prices, provided that the daily cost does not exceed RMB 3 for western medicines and RMB 5 for traditional Chinese medicines.
In this instance, Zhejiang Province has taken the initiative to allow enterprises to raise prices of low-cost drugs within a certain range under national standards, which can be regarded as an important practical measure in liberalizing drug pricing.
The notice also pointed out that, following the implementation of the rules for medical insurance payment standards, the prices of low-cost drugs shall be administered in accordance with the policies governing such standards.
Furthermore, the Notice states that for non-winning bid drugs within the scope of basic medical insurance coverage (excluding emergency drugs), if long-term record-based procurement is required, medical institutions shall submit applications to the Provincial Health and Family Planning Commission in accordance with the provisions of the "Zhejiang Province Online Centralized Drug Procurement Record-Based Procurement Management Measures (Trial)." Upon review by the Provincial Health and Family Planning Commission and the Provincial Department of Human Resources and Social Security, the measures shall be implemented after being announced by the Office of the Leading Group for Provincial Centralized Drug Procurement.
→_→ Data
◆Next 5 Years: Global Pharmaceutical Market to Reach Trillions, Anti-Cancer Drugs Near $150 Billion, and Tumor Immunotherapy Hits $40 Billion
Over the next five years, the global pharmaceutical market is projected to grow at a compound annual growth rate (CAGR) of 4%–7%, reaching $1.27 trillion by 2018. Within this market, generics are expected to expand at a rate of 7%–10%, attaining a value of $606 billion by 2018 and accounting for 48% of the total pharmaceutical market size.
Last year, the anticancer drug market generated $100 billion in revenue. By 2018, the market is projected to reach $147 billion, with a compound annual growth rate (CAGR) of 11.6%, indicating that the research and development of anticancer drugs can yield substantial profits.
According to forecasts by Goldman Sachs, the market for cancer immunotherapy was expected to reach $31 billion by 2020, while consulting firm Leerink Partners projected that the market would grow to $40 billion over the following decade.
Currently, the global anti-cancer drug market is largely dominated by Roche, Novartis, Merck & Co., and Bristol-Myers Squibb. However, Pfizer, known for producing Viagra (for erectile dysfunction) and Lipitor (a cholesterol-lowering medication), has recently expressed its intention to enter this market.
◆GlobalData: The Global HIV/AIDS Therapy Market Will Reach $15.3 Billion in 2023.
According to a report by the research and consulting firm GlobalData,The market value of human immunodeficiency virus (HIV) therapies will increase from $14 billion in 2013 to $15.3 billion in 2023, with a compound annual growth rate (CAGR) of 0.9% across the nine major markets (the United States, France, Germany, Italy, Spain, the United Kingdom, Japan, Brazil, and China)., representing a lower compound annual growth rate.
Moreover, although the overall market size for HIV/AIDS will remain relatively stable in the coming years, the HIV/AIDS therapeutics market is expected to shift toward integrase inhibitors and single-tablet regimens. This trend is particularly pronounced in the United States, as fiscal austerity measures continue to be the primary obstacle to market growth in other countries.
However, GlobalData’s report indicates that integrase inhibitors for HIV treatment, such as ViiV Healthcare’s Triumeq and Gilead’s Quad 2, will offset the impact of generic drugs on the market in the coming years.
◆Global Biopharmaceutical Market: Set to Expand to $600 Billion Over the Next Seven Years.
According to Grand View Research, the global biotechnology market size was $270.5 billion in 2013, driven by growing demand for recombinant technology, pharmaceutical biotechnology, and DNA sequencing technologies in disease diagnosis and treatment.The global biotechnology market is projected to grow at a compound annual growth rate (CAGR) of 12.3%, reaching $606.8 billion by 2020.
→_→ New Technology
◆China’s First Intelligent Digital Hearing Aid Chip Successfully Developed.
Recently, China’s first intelligent digital hearing aid chip was successfully developed by the Institute of Microelectronics of the Chinese Academy of Sciences. As the country’s first core System-on-Chip (SoC) for hearing aids, it represents a true single-chip, fully integrated hearing aid solution. The chip has passed industry-standard testing for hearing aids, with its performance and power consumption metrics meeting the requirements for international mid-range hearing aid products.
The hearing aid SoC chip adopts a single-chip fully integrated solution, in which the low-noise AFE includes an adaptive pre-amplification circuit (PGA) and a low-noise 16-bit ADC; the low-power DSP comprises an Application-Specific Instruction-set Processor (ASIP) and several coprocessors. Based on this SoC chip, a typical hearing aid system can be built by simply equipping it with a microphone, speaker, EEPROM, zinc-air battery, and a few capacitors. This SoC chip can also be programmed for applications in other fields such as sound acquisition and speech noise reduction.
◆Massachusetts General Hospital Develops New Smartphone-Connected Device for Rapid Cancer Diagnosis.
Two researchers at Massachusetts General Hospital have developed a device, D3, that can deliver cancer diagnostic results within one hour using only a smartphone, eliminating the need for invasive biopsies.
The D3 or Digital Splitting Diagnostic System is a compact device that connects to a smartphone camera, transforming it into a powerful microscope for analyzing samples from blood, fine-needle aspiration biopsies, Pap smears, or sparse cell populations. The system utilizes specialized antibodies that cause cancer cells to fluoresce upon detection.
The device has undergone cohort testing to compare its performance against diagnostic results from expert clinicians. One of the test objectives was to classify cervical biopsy samples as high-risk, low-risk, or benign; another objective was to differentiate among four types of benign and malignant tumors.
→_→ Capital
